Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
| 0.169 | |
| 0.169 | |
| - | |
| 0.169 | |
| 0.169 | |
| 0.072-0.4 | |
| 19 143 K | |
| 0.018 | |
| 113 M | |
| 0 | |
| 0 | |
| 0.901 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Codexis, Inc. REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the...
LOS ANGELES, Aug. 09, 2019 (GLOBE NEWSWIRE) -- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC), today issued the following announcement. The following is being released pursuan...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
